SR-717
产品说明书
 |
同义名 : | SR-717 lithium;SR 717 (lithium salt) |
| CAS号 : | 2375421-09-1 | |
| 货号 : | A1340104 | |
| 分子式 : | C15H8F2LiN5O3 | |
| 纯度 : | 99%+ | |
| 分子量 : | 351.193 | |
| MDL号 : | N/A | |
| 存储条件： |
Pure form Inert atmosphere,Room Temperature In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 20 mg/mL(56.95 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Stimulator of interferon genes (STING) is an endoplasmic reticulum signaling protein which has been demonstrated to play essential roles in antitumor immunity. SR-717 is a non-nucleotide, small-molecule STING agonist with an IC50 of 7.8 μM. Within the CD45.2+ population, SR-717 treatment resulted in a significant increase in the frequency of CD8 T cells among TILs (tumor infiltrating lymphocytes) and a decrease in the frequencies of NK cells within the draining lymphnode (dLN) and spleen. In WT C57BL/6 mice, SR-717 induced IFN-β after intraperitoneal administration in a dose-dependent manner. In WT or Stinggt/gt mice, a 30 mg/kg intraperitoneal once-per-day regimen of SR-717 for 1 week was found to maximally inhibit B16.F10 tumor growth. In C57BL/6 mice bearing B16.F10 cells, SR-717 (15 mg/kg; dosed intraperitoneally; once per day) significantly inhibited the formation of pulmonary nodules in this model of metastasis. SR-717 (30 mg/kg intraperitoneally) displayed a better level of efficacy than anti-PD-1 or anti-PD-L1 antibody therapy on reducing tumor burden and improving overall survival in the B16.F10 model[2]. | ||
| 作用机制 | The structure of SR-717 facilitates a binding mode in which Thr263 side chain hydroxyls from both monomers are positioned to form hydrogen-bond interactions with SR-717[2]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.85mL 0.57mL 0.28mL |
14.24mL 2.85mL 1.42mL |
28.47mL 5.69mL 2.85mL |
| 参考文献 |
|---|